- Breast tomosynthesis, a next-generation 3D mammography technology, is becoming a key diagnostic tool in breast cancer detection due to its enhanced imaging accuracy, reduced false positives, and superior detection in dense breast tissues, making it increasingly essential in both hospital and diagnostic center settings
- The accelerating demand for breast tomosynthesis is primarily fueled by the rising global incidence of breast cancer, growing public awareness around early screening, and expanding government support for breast health initiatives and imaging infrastructure upgrades
- North America dominated the breast tomosynthesis market with the largest revenue share of 42.3% in 2024, driven by high screening rates, favorable reimbursement policies, and the strong presence of industry leaders, especially in the U.S., where rapid technology adoption and preventive health focus are propelling growth in both hospitals and independent imaging centers
- Asia-Pacific is expected to be the fastest growing region in the breast tomosynthesis market during the forecast period due to improving healthcare access, increasing public-private investments in diagnostic technologies, and heightened awareness campaigns in countries such as China, India, and South Korea
- 2D/3D combination systems segment dominated the breast tomosynthesis market with a market share of 67.8% in 2024, supported by their clinical versatility, ease of integration into existing workflows, and wider regulatory acceptance in routine breast cancer screenings
